Ec50 Value
Ec50 Value - Related Videos
07:24
Xenopus Oocytes: Optimized Methods for Microinjection, Removal of Follicular Cell Layers, and Fast Solution Changes in Electrophysiological Experiments
0 Views •
Cited by 5 •
2016
Optimized procedures for the isolation of single follicles, cytoplasmic RNA microinjections, the removal of surrounding cell layers, and protein expression in Xenopus oocytes are described. In addition, a simple method for fast solution changes in electrophysiological experiments with ligand-gated ion channels is presented.
08:09
Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis
0 Views •
Cited by 12 •
2017
MicroScale Thermophoresis (MST) is a sensitive technology to characterize aptamer-target interactions. This manuscript describes an MST protocol to characterize aptamer-small molecule interactions.
16:07
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
0 Views •
Cited by 1 •
2017
A protocol for the determination of the relative anti-apoptotic activity of an anti-TNFα mAb using a neutralization mechanism with WEHI 164 cells is presented here. This protocol is useful for comparing the neutralization strength of different molecules with the same biological functionality.
08:32
The ATP Bioluminescence Assay
0 Views •
2023
In fireflies, the luciferase enzyme converts a compound called luciferin into oxyluciferin, and produces light or “luminescence” as a result. This reaction requires energy derived from ATP in order to proceed, so researchers have exploited the luciferase-luciferin interaction to gauge ATP levels in cells. Given ATP’s role as the cell’s currency of energy, the ATP bioluminescence assay can provide insight into cellular metabolism and overall cell health.In this video, JoVE discusses cellular...
10:13
Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
0 Views •
Cited by 11 •
2017
Guanosine triphosphate (GTP) binding is one of the earliest events in G-Protein-Coupled Receptor (GPCR) activation. This protocol describes how to pharmacologically characterize specific GPCR-ligand interactions by monitoring the binding of the radio-labeled GTP analog, [35S]guanosine-5'-O-(3-thio)triphosphate ([35S]GTPγS), in response to a ligand of interest.
FAQs
Potency and efficacy describe different properties. EC50 is used to compare how much compound is needed to reach a defined response level, whereas maximum efficacy describes the greatest effect observed. A compound can therefore show a favorable EC50 but a lower maximum response, so potency rankings should not be treated as complete measures of pharmacological performance.
The sigmoidal concentration-response model helps estimate the midpoint of a response curve rather than relying only on a single measured concentration. Its curve shape shows how response changes across concentrations, while the midpoint supplies the EC50 estimate. Examining both features helps investigators judge whether the fitted value represents the observed pharmacological response.
Experimental conditions can influence EC50 comparisons. Results should be interpreted with the assay context, including whether the response came from cells or tissue and how the concentration-response relationship was measured. Comparing values without considering those conditions can make compounds appear more or less potent than they are within the original experimental setting.
In receptor-mediated pharmacology, an EC50 links concentration to the response produced through the system being studied. This makes the value useful for characterizing receptor-mediated responses, but it does not by itself describe the entire response profile. Maximum efficacy and curve shape add information about the system’s functional behavior.
Researchers collect responses across a range of compound concentrations and represent those observations as a concentration-response curve. They then identify the concentration associated with the midpoint response, often by applying a sigmoidal model. This workflow converts assay measurements into a potency value that can support pharmacological analysis and compound comparison.
Cell-based and tissue assays provide settings in which concentration-response behavior can be measured. In these experiments, the EC50 value helps investigators compare active compounds within the assay and characterize how receptor-mediated responses change with concentration. The result can support drug screening, but its meaning remains tied to the experimental system in which it was measured.
During drug screening or dose selection, EC50 values can inform potency comparisons and help organize experimental choices. The most reliable interpretation combines the estimated midpoint with maximum efficacy, curve shape, and assay conditions. This approach reduces the risk of treating one potency number as sufficient evidence for overall activity or for direct comparison across studies.